Haemodynamic definitions and updated clinical classification of pulmonary hypertension

Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2019-01, Vol.53 (1), p.1801913
Hauptverfasser: Simonneau, Gérald, Montani, David, Celermajer, David S, Denton, Christopher P, Gatzoulis, Michael A, Krowka, Michael, Williams, Paul G, Souza, Rogerio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 1801913
container_title The European respiratory journal
container_volume 53
creator Simonneau, Gérald
Montani, David
Celermajer, David S
Denton, Christopher P
Gatzoulis, Michael A
Krowka, Michael
Williams, Paul G
Souza, Rogerio
description Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management.Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
doi_str_mv 10.1183/13993003.01913-2018
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6351336</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157672645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-4bbaa2a903b1fca81c70d2c044a71c3e524332faf6bd5301531c7982375475783</originalsourceid><addsrcrecordid>eNpdUU1v1DAQtRAVXRZ-ARLKEQ5pZzx2Pi5IVVXYSiv1UrhajuOwRokd4qTS_nsctq0opxm9ee_NjB5jHxAuECu6RKprAqALwBop54DVK7ZZ0XyFX7MN1EA51lScs7cx_gLAQhC-YecEUsi6qDbsx07bIbRHrwdnstZ2zrvZBR8z7dtsGVs92zYzfYKN7lOjY3Rd6ldSFrpsXPoheD0ds8NxtNNsfUyTd-ys03207x_rln3_enN_vcv3d99ur6_2uZEg51w0jdZcpzMb7Iyu0JTQcgNC6BINWckFEe90VzStJEBJiVFXnEopSllWtGVfTr7j0gy2NdbPk-7VOLkhnaSCdurlxLuD-hkeVEESiYpk8PlkcPhPtrvaqxUDIUlwqB4wcT89LpvC78XGWQ0uGtv32tuwRMVRlkXJi6TYMjpRzRRinGz37I2g1vTUU3rqb3pqTS-pPv77zbPmKS76A_SAlho</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157672645</pqid></control><display><type>article</type><title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Simonneau, Gérald ; Montani, David ; Celermajer, David S ; Denton, Christopher P ; Gatzoulis, Michael A ; Krowka, Michael ; Williams, Paul G ; Souza, Rogerio</creator><creatorcontrib>Simonneau, Gérald ; Montani, David ; Celermajer, David S ; Denton, Christopher P ; Gatzoulis, Michael A ; Krowka, Michael ; Williams, Paul G ; Souza, Rogerio</creatorcontrib><description>Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP &gt;20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP &gt;20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management.Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.01913-2018</identifier><identifier>PMID: 30545968</identifier><language>eng</language><publisher>England: European Respiratory Society</publisher><subject>Human health and pathology ; Life Sciences ; Pulmonology and respiratory tract ; Series</subject><ispartof>The European respiratory journal, 2019-01, Vol.53 (1), p.1801913</ispartof><rights>Copyright ©ERS 2019.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright ©ERS 2019 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-4bbaa2a903b1fca81c70d2c044a71c3e524332faf6bd5301531c7982375475783</citedby><cites>FETCH-LOGICAL-c505t-4bbaa2a903b1fca81c70d2c044a71c3e524332faf6bd5301531c7982375475783</cites><orcidid>0000-0003-2789-9143 ; 0000-0002-9358-6922</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30545968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04534208$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Simonneau, Gérald</creatorcontrib><creatorcontrib>Montani, David</creatorcontrib><creatorcontrib>Celermajer, David S</creatorcontrib><creatorcontrib>Denton, Christopher P</creatorcontrib><creatorcontrib>Gatzoulis, Michael A</creatorcontrib><creatorcontrib>Krowka, Michael</creatorcontrib><creatorcontrib>Williams, Paul G</creatorcontrib><creatorcontrib>Souza, Rogerio</creatorcontrib><title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP &gt;20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP &gt;20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management.Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.</description><subject>Human health and pathology</subject><subject>Life Sciences</subject><subject>Pulmonology and respiratory tract</subject><subject>Series</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdUU1v1DAQtRAVXRZ-ARLKEQ5pZzx2Pi5IVVXYSiv1UrhajuOwRokd4qTS_nsctq0opxm9ee_NjB5jHxAuECu6RKprAqALwBop54DVK7ZZ0XyFX7MN1EA51lScs7cx_gLAQhC-YecEUsi6qDbsx07bIbRHrwdnstZ2zrvZBR8z7dtsGVs92zYzfYKN7lOjY3Rd6ldSFrpsXPoheD0ds8NxtNNsfUyTd-ys03207x_rln3_enN_vcv3d99ur6_2uZEg51w0jdZcpzMb7Iyu0JTQcgNC6BINWckFEe90VzStJEBJiVFXnEopSllWtGVfTr7j0gy2NdbPk-7VOLkhnaSCdurlxLuD-hkeVEESiYpk8PlkcPhPtrvaqxUDIUlwqB4wcT89LpvC78XGWQ0uGtv32tuwRMVRlkXJi6TYMjpRzRRinGz37I2g1vTUU3rqb3pqTS-pPv77zbPmKS76A_SAlho</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Simonneau, Gérald</creator><creator>Montani, David</creator><creator>Celermajer, David S</creator><creator>Denton, Christopher P</creator><creator>Gatzoulis, Michael A</creator><creator>Krowka, Michael</creator><creator>Williams, Paul G</creator><creator>Souza, Rogerio</creator><general>European Respiratory Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2789-9143</orcidid><orcidid>https://orcid.org/0000-0002-9358-6922</orcidid></search><sort><creationdate>20190101</creationdate><title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</title><author>Simonneau, Gérald ; Montani, David ; Celermajer, David S ; Denton, Christopher P ; Gatzoulis, Michael A ; Krowka, Michael ; Williams, Paul G ; Souza, Rogerio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-4bbaa2a903b1fca81c70d2c044a71c3e524332faf6bd5301531c7982375475783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Human health and pathology</topic><topic>Life Sciences</topic><topic>Pulmonology and respiratory tract</topic><topic>Series</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simonneau, Gérald</creatorcontrib><creatorcontrib>Montani, David</creatorcontrib><creatorcontrib>Celermajer, David S</creatorcontrib><creatorcontrib>Denton, Christopher P</creatorcontrib><creatorcontrib>Gatzoulis, Michael A</creatorcontrib><creatorcontrib>Krowka, Michael</creatorcontrib><creatorcontrib>Williams, Paul G</creatorcontrib><creatorcontrib>Souza, Rogerio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simonneau, Gérald</au><au>Montani, David</au><au>Celermajer, David S</au><au>Denton, Christopher P</au><au>Gatzoulis, Michael A</au><au>Krowka, Michael</au><au>Williams, Paul G</au><au>Souza, Rogerio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>53</volume><issue>1</issue><spage>1801913</spage><pages>1801913-</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP &gt;20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP &gt;20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management.Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.</abstract><cop>England</cop><pub>European Respiratory Society</pub><pmid>30545968</pmid><doi>10.1183/13993003.01913-2018</doi><orcidid>https://orcid.org/0000-0003-2789-9143</orcidid><orcidid>https://orcid.org/0000-0002-9358-6922</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2019-01, Vol.53 (1), p.1801913
issn 0903-1936
1399-3003
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6351336
source EZB-FREE-00999 freely available EZB journals
subjects Human health and pathology
Life Sciences
Pulmonology and respiratory tract
Series
title Haemodynamic definitions and updated clinical classification of pulmonary hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T03%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Haemodynamic%20definitions%20and%20updated%20clinical%20classification%20of%20pulmonary%20hypertension&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Simonneau,%20G%C3%A9rald&rft.date=2019-01-01&rft.volume=53&rft.issue=1&rft.spage=1801913&rft.pages=1801913-&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.01913-2018&rft_dat=%3Cproquest_pubme%3E2157672645%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157672645&rft_id=info:pmid/30545968&rfr_iscdi=true